Davies, MJ, Baldry, EL, Bodicoat, DH, Chatterjee, S, Edwardson, CL, Gray, LJ, Khunti, K, Sargeant, JA, Stensel, DJ, Webb, DR et al (show 4 more authors)
(2020)
The SGLT2 inhibitor empagliflozin does not stimulate compensatory appetite responses in patients with excess adiposity and type 2 diabetes.
.
Text
EASD abstract V3 24 3 2020.docx - Author Accepted Manuscript Download (29kB) |
Item Type: | Conference or Workshop Item (Unspecified) |
---|---|
Depositing User: | Symplectic Admin |
Date Deposited: | 15 Oct 2020 08:28 |
Last Modified: | 18 Jan 2023 23:30 |
Related URLs: | |
URI: | https://livrepository.liverpool.ac.uk/id/eprint/3103645 |
Share
CORE (COnnecting REpositories)